Molecular Partners AG
SIX:MOLN

Watchlist Manager
Molecular Partners AG Logo
Molecular Partners AG
SIX:MOLN
Watchlist
Price: 4.85 CHF 0.73% Market Closed
Market Cap: 178.8m CHF
Have any thoughts about
Molecular Partners AG?
Write Note

Molecular Partners AG
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Molecular Partners AG
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Molecular Partners AG
SIX:MOLN
Additional Paid In Capital
CHf367.5m
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Additional Paid In Capital
$1.2B
CAGR 3-Years
6%
CAGR 5-Years
21%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Additional Paid In Capital
CHf477.1m
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Additional Paid In Capital
$3.3B
CAGR 3-Years
8%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Additional Paid In Capital
CHf1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Molecular Partners AG
Glance View

Market Cap
178.8m CHF
Industry
Biotechnology

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

MOLN Intrinsic Value
3.07 CHF
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Molecular Partners AG's Additional Paid In Capital?
Additional Paid In Capital
367.5m CHF

Based on the financial report for Jun 30, 2024, Molecular Partners AG's Additional Paid In Capital amounts to 367.5m CHF.

What is Molecular Partners AG's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
15%

Over the last year, the Additional Paid In Capital growth was 1%. The average annual Additional Paid In Capital growth rates for Molecular Partners AG have been 1% over the past three years , 15% over the past five years .

Back to Top